indomethacin has been researched along with Malignant Melanoma in 45 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Because of the additive antitumor effects of interleukin 1 alpha (IL-1 alpha) and indomethacin in vivo, we conducted a phase II trial of this combination in patients with melanoma." | 9.08 | Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma. ( Alvord, WG; Beauchamp, AE; Conlon, KC; Creekmore, SP; Curti, BD; Fenton, RG; Gause, BL; Holmlund, JT; Janik, JE; Kopp, WC; Longo, DL; Miller, LL; Oppenheim, JJ; Powers, GC; Sharfman, WH; Smith, JW; Steis, RG; Sznol, M; Urba, WJ, 1996) |
| "As a result of preclinical data demonstrating the antitumour and antimetastatic efficiency of indomethacin in murine models, and the clinical observation of occasional tumour regression in patients with advanced melanoma treated with indomethacin together with ranitidine, a Phase II study was performed of prolonged administration of these two oral agents in combination." | 9.08 | Oral indomethacin and ranitidine in advanced melanoma: a phase II study. ( Lohmann, RC; Mertens, WC, 1996) |
| "The results demonstrated that indomethacin added in vitro enhanced LPR in early stage melanoma patients before therapy." | 9.08 | Effect of T-activin therapy on indomethacin modulation of lymphoproliferative response in vitro of melanoma patients. ( Milosević, D; Sasić, M; Stanojević-Bakić, N; Vucković-Dekić, L, 1998) |
| "Preclinical models of advanced melanoma have shown that chronic indomethacin therapy combined with interleukin 2 (IL-2) can eradicate experimental metastases." | 9.07 | Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2. ( Banerjee, D; Bramwell, VH; Gwadry-Sridhar, F; Lala, PK; Mertens, WC; Romano, W, 1992) |
| " We conducted a prospective randomized trial of alpha-interferon given with or without indomethacin to patients with malignant melanoma to determine what effect, if any, indomethacin might have on the toxic, immunomodulatory, and therapeutic properties of interferon in this disease." | 9.06 | Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. ( Clark, JW; Crum, E; Hawkins, MJ; Jones, MJ; Longo, DL; McKnight, JE; Miller, RL; Smith, JW; Steis, RG; Urba, WJ, 1989) |
| "Malignant murine melanoma (BL6) cells cultured in vitro were supplemented with indomethacin (0." | 7.69 | Effect of vitamin E and indomethacin treatment on adenylate cyclase activity, PGE2 and cAMP levels in murine melanoma cells. ( Duncan, JR; Ottino, P, 1997) |
| "Interleukin-2 (IL-2) production following concanavalin A stimulation and the response of peripheral blood mononuclear cells (PBMC) to both IL-2 alone and IL-2 plus indomethacin, a prostaglandin synthetase inhibitor, were examined in 16 melanoma patients and 12 healthy controls." | 7.67 | In vitro inhibition of interleukin-2 production by peripheral blood lymphocytes from stage III melanoma patients by prostaglandin E2: enhancement of lymphocyte proliferation by exogenous interleukin-2 plus indomethacin. ( Dowd, J; Hersh, EM; Murray, JL, 1986) |
| "Indomethacin significantly enhances the depressed levels of lymphocyte proliferation to the mitogens phytohemagglutinin and concanavalin A in melanoma patients." | 7.66 | Immune modulatory effects of indomethacin in melanoma patients are not related to prostaglandin E2-mediated suppression. ( Balch, CM; Tilden, AB, 1982) |
| "Indomethacin (IND) is a well-known drug used worldwide." | 5.56 | Anti-Melanoma Activity of Indomethacin Incorporated into Mesoporous Silica Nanoparticles. ( Braz, WR; do Nascimento, S; Fernandes, FS; Ferreira, NH; Nassar, EJ; Ribeiro, AB; Rinaldi-Neto, F; Tavares, DC, 2020) |
| "Chronic inflammation has long been associated with neoplastic progression." | 5.35 | Leukotriene B4 creates a favorable microenvironment for murine melanoma growth. ( Bachi, AL; Carneiro, CR; Correa, M; Jasiulionis, MG; Kim, FJ; Lopes, JD; Nonogaki, S, 2009) |
| "Skin metastasis of malignant melanoma has been difficult to control by chemoimmunotherapy." | 5.27 | [Control of multiple skin and lung metastasis of malignant melanoma by combined DAV and OK-432 chemoimmunotherapy in association with large-scale administration of indomethacin]. ( Jimbow, K; Kawamura, M; Maeda, K; Miura, S, 1984) |
| "If indomethacin treatment was initiated prior to transplantation of the tumor or 2 weeks post-transplantation, and continued throughout the disease process, there was no effect on either the course of the disease or mortality." | 5.27 | Increased sensitivity to indomethacin of mice bearing the BCL1-leukemia. ( Hart, DA, 1984) |
| "Because of the additive antitumor effects of interleukin 1 alpha (IL-1 alpha) and indomethacin in vivo, we conducted a phase II trial of this combination in patients with melanoma." | 5.08 | Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma. ( Alvord, WG; Beauchamp, AE; Conlon, KC; Creekmore, SP; Curti, BD; Fenton, RG; Gause, BL; Holmlund, JT; Janik, JE; Kopp, WC; Longo, DL; Miller, LL; Oppenheim, JJ; Powers, GC; Sharfman, WH; Smith, JW; Steis, RG; Sznol, M; Urba, WJ, 1996) |
| "As a result of preclinical data demonstrating the antitumour and antimetastatic efficiency of indomethacin in murine models, and the clinical observation of occasional tumour regression in patients with advanced melanoma treated with indomethacin together with ranitidine, a Phase II study was performed of prolonged administration of these two oral agents in combination." | 5.08 | Oral indomethacin and ranitidine in advanced melanoma: a phase II study. ( Lohmann, RC; Mertens, WC, 1996) |
| "The results demonstrated that indomethacin added in vitro enhanced LPR in early stage melanoma patients before therapy." | 5.08 | Effect of T-activin therapy on indomethacin modulation of lymphoproliferative response in vitro of melanoma patients. ( Milosević, D; Sasić, M; Stanojević-Bakić, N; Vucković-Dekić, L, 1998) |
| "Preclinical models of advanced melanoma have shown that chronic indomethacin therapy combined with interleukin 2 (IL-2) can eradicate experimental metastases." | 5.07 | Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2. ( Banerjee, D; Bramwell, VH; Gwadry-Sridhar, F; Lala, PK; Mertens, WC; Romano, W, 1992) |
| " We conducted a prospective randomized trial of alpha-interferon given with or without indomethacin to patients with malignant melanoma to determine what effect, if any, indomethacin might have on the toxic, immunomodulatory, and therapeutic properties of interferon in this disease." | 5.06 | Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. ( Clark, JW; Crum, E; Hawkins, MJ; Jones, MJ; Longo, DL; McKnight, JE; Miller, RL; Smith, JW; Steis, RG; Urba, WJ, 1989) |
| " The direct cytotoxicity of piroxicam indomethacin, and aspirin against 4 canine tumor cell lines (transitional cell carcinoma, squamous cell carcinoma, melanoma, and soft tissue sarcoma) was determined in short-term growth rate assays and in clonogenic assays." | 3.69 | Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. ( Chan, TC; Knapp, DW; Kuczek, T; Park, B; Reagan, WJ, 1995) |
| " We report here that inhibitors of both the cyclooxygenase and lipoxygenase pathways of arachidonic acid metabolism convert mouse melanoma and human fibrosarcoma cells to a non invasive state by reducing the production of MMP-2, an enzyme required for the degradation of basement membranes." | 3.69 | Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. ( Martin, GR; Reich, R, 1996) |
| "Malignant murine melanoma (BL6) cells cultured in vitro were supplemented with indomethacin (0." | 3.69 | Effect of vitamin E and indomethacin treatment on adenylate cyclase activity, PGE2 and cAMP levels in murine melanoma cells. ( Duncan, JR; Ottino, P, 1997) |
| "Interleukin-2 (IL-2) production following concanavalin A stimulation and the response of peripheral blood mononuclear cells (PBMC) to both IL-2 alone and IL-2 plus indomethacin, a prostaglandin synthetase inhibitor, were examined in 16 melanoma patients and 12 healthy controls." | 3.67 | In vitro inhibition of interleukin-2 production by peripheral blood lymphocytes from stage III melanoma patients by prostaglandin E2: enhancement of lymphocyte proliferation by exogenous interleukin-2 plus indomethacin. ( Dowd, J; Hersh, EM; Murray, JL, 1986) |
| "The histamine-2 receptor antagonist cimetidine (10(-5)M) and the prostaglandin synthesis inhibitor indomethacin (10(-8)M) augmented natural killer cell activity in the majority of healthy controls and patients with advanced melanoma and in a lower frequency of patients with colorectal carcinoma." | 3.67 | Influence in vitro on NK and K cell activities by cimetidine and indomethacin with and without simultaneous exposure to interferon. ( Flodgren, P; Sjögren, HO, 1985) |
| "Indomethacin significantly enhances the depressed levels of lymphocyte proliferation to the mitogens phytohemagglutinin and concanavalin A in melanoma patients." | 3.66 | Immune modulatory effects of indomethacin in melanoma patients are not related to prostaglandin E2-mediated suppression. ( Balch, CM; Tilden, AB, 1982) |
| "Prostaglandin D2 was able to reduce in vitro aggregation of platelets from C57 black mice." | 2.36 | Prostaglandins and metastasis. ( Stringfellow, DA, 1983) |
| "Indomethacin (IND) is a well-known drug used worldwide." | 1.56 | Anti-Melanoma Activity of Indomethacin Incorporated into Mesoporous Silica Nanoparticles. ( Braz, WR; do Nascimento, S; Fernandes, FS; Ferreira, NH; Nassar, EJ; Ribeiro, AB; Rinaldi-Neto, F; Tavares, DC, 2020) |
| "Chronic inflammation has long been associated with neoplastic progression." | 1.35 | Leukotriene B4 creates a favorable microenvironment for murine melanoma growth. ( Bachi, AL; Carneiro, CR; Correa, M; Jasiulionis, MG; Kim, FJ; Lopes, JD; Nonogaki, S, 2009) |
| " This schedule was repeated at least twice more with a one-week interval between cycles, usually at the same dosage level." | 1.28 | Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma. ( Boswell, WD; Bradley, EC; Dean, G; Harel, W; Kempf, RA; Lind, S; Mitchell, MS; Moore, J; Shau, H, 1989) |
| "Skin metastasis of malignant melanoma has been difficult to control by chemoimmunotherapy." | 1.27 | [Control of multiple skin and lung metastasis of malignant melanoma by combined DAV and OK-432 chemoimmunotherapy in association with large-scale administration of indomethacin]. ( Jimbow, K; Kawamura, M; Maeda, K; Miura, S, 1984) |
| "Treatment with indomethacin blocks prostaglandin synthesis and induces thermosensitivity." | 1.27 | Natural thermal resistance of human tumor cells and the role of prostaglandin. ( Hildebrand-Zanki, S; Kern, DH; Morton, DL; Roe, DJ; Storm, FK; Worth, GD, 1983) |
| "If indomethacin treatment was initiated prior to transplantation of the tumor or 2 weeks post-transplantation, and continued throughout the disease process, there was no effect on either the course of the disease or mortality." | 1.27 | Increased sensitivity to indomethacin of mice bearing the BCL1-leukemia. ( Hart, DA, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (60.00) | 18.7374 |
| 1990's | 10 (22.22) | 18.2507 |
| 2000's | 4 (8.89) | 29.6817 |
| 2010's | 3 (6.67) | 24.3611 |
| 2020's | 1 (2.22) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira, NH | 1 |
| Ribeiro, AB | 1 |
| Rinaldi-Neto, F | 1 |
| Fernandes, FS | 1 |
| do Nascimento, S | 1 |
| Braz, WR | 1 |
| Nassar, EJ | 1 |
| Tavares, DC | 1 |
| Tse, AK | 1 |
| Cao, HH | 1 |
| Cheng, CY | 1 |
| Kwan, HY | 1 |
| Yu, H | 1 |
| Fong, WF | 1 |
| Yu, ZL | 1 |
| Somasundaram, R | 1 |
| Herlyn, M | 1 |
| Patel, T | 1 |
| Kirsner, RS | 1 |
| Bachi, AL | 1 |
| Kim, FJ | 1 |
| Nonogaki, S | 1 |
| Carneiro, CR | 1 |
| Lopes, JD | 1 |
| Jasiulionis, MG | 1 |
| Correa, M | 1 |
| Roh, JL | 1 |
| Sung, MW | 1 |
| Kim, KH | 1 |
| Axelsson, H | 1 |
| Lönnroth, C | 1 |
| Wang, W | 1 |
| Svanberg, E | 1 |
| Lundholm, K | 1 |
| Stringfellow, DA | 2 |
| Minassian, AA | 1 |
| Kadagidze, ZG | 1 |
| Murray, JL | 3 |
| Kollmorgen, GM | 1 |
| Tilden, AB | 2 |
| Balch, CM | 3 |
| Maeda, K | 1 |
| Miura, S | 1 |
| Kawamura, M | 1 |
| Jimbow, K | 1 |
| Storm, FK | 1 |
| Roe, DJ | 1 |
| Hildebrand-Zanki, S | 1 |
| Worth, GD | 1 |
| Morton, DL | 1 |
| Kern, DH | 1 |
| Plescia, OJ | 1 |
| Pontieri, GM | 1 |
| Brown, J | 1 |
| Racis, S | 1 |
| Ippoliti, F | 1 |
| Bellelli, L | 1 |
| Sezzi, ML | 1 |
| Lipari, M | 1 |
| Hart, DA | 1 |
| Hofer, D | 1 |
| Dubitsky, AM | 1 |
| Reïlly, P | 1 |
| Santoro, MG | 3 |
| Jaffe, BM | 3 |
| Favalli, C | 1 |
| Garaci, E | 1 |
| Etheredge, E | 1 |
| Knapp, DW | 1 |
| Chan, TC | 1 |
| Kuczek, T | 1 |
| Reagan, WJ | 1 |
| Park, B | 1 |
| Mertens, WC | 3 |
| Bramwell, VH | 2 |
| Banerjee, D | 2 |
| Gwadry-Sridhar, F | 2 |
| Lala, PK | 2 |
| Roth, MD | 1 |
| Golub, SH | 1 |
| Janik, JE | 1 |
| Miller, LL | 1 |
| Longo, DL | 2 |
| Powers, GC | 1 |
| Urba, WJ | 2 |
| Kopp, WC | 1 |
| Gause, BL | 1 |
| Curti, BD | 1 |
| Fenton, RG | 1 |
| Oppenheim, JJ | 2 |
| Conlon, KC | 1 |
| Holmlund, JT | 1 |
| Sznol, M | 1 |
| Sharfman, WH | 1 |
| Steis, RG | 2 |
| Creekmore, SP | 1 |
| Alvord, WG | 1 |
| Beauchamp, AE | 1 |
| Smith, JW | 2 |
| Lohmann, RC | 1 |
| Reich, R | 1 |
| Martin, GR | 1 |
| Ottino, P | 1 |
| Duncan, JR | 1 |
| Stanojević-Bakić, N | 1 |
| Vucković-Dekić, L | 1 |
| Milosević, D | 1 |
| Sasić, M | 1 |
| Schecter, AD | 1 |
| Spirn, B | 1 |
| Rossikhina, M | 1 |
| Giesen, PL | 1 |
| Bogdanov, V | 1 |
| Fallon, JT | 1 |
| Fisher, EA | 1 |
| Schnapp, LM | 1 |
| Nemerson, Y | 1 |
| Taubman, MB | 1 |
| Fitzpatrick, FA | 1 |
| Vosixa, G | 1 |
| Thies, J | 1 |
| Philpott, GW | 1 |
| Romano, W | 1 |
| Hamblin, TJ | 1 |
| Ishihara, K | 1 |
| Mitchell, MS | 1 |
| Kempf, RA | 1 |
| Harel, W | 1 |
| Shau, H | 1 |
| Boswell, WD | 1 |
| Lind, S | 1 |
| Dean, G | 1 |
| Moore, J | 1 |
| Bradley, EC | 1 |
| Miller, RL | 1 |
| Clark, JW | 1 |
| Crum, E | 1 |
| McKnight, JE | 1 |
| Hawkins, MJ | 1 |
| Jones, MJ | 1 |
| Itoh, K | 1 |
| Pellis, NR | 1 |
| Talmadge, JE | 1 |
| Bowersox, O | 1 |
| Tribble, H | 1 |
| Lee, SH | 1 |
| Shepard, HM | 1 |
| Liggitt, D | 1 |
| Hilario, E | 1 |
| Unda, F | 1 |
| Aliño, SF | 1 |
| Sosman, JA | 1 |
| Kohler, PC | 1 |
| Hank, JA | 1 |
| Moore, KH | 1 |
| Bechhofer, R | 1 |
| Storer, B | 1 |
| Sondel, PM | 1 |
| Dowd, J | 1 |
| Hersh, EM | 1 |
| Flodgren, P | 1 |
| Sjögren, HO | 1 |
| Onozaki, K | 1 |
| Matsushima, K | 1 |
| Kleinerman, ES | 1 |
| Saito, T | 1 |
| Poutsiaka, DD | 1 |
| Taylor, DD | 1 |
| Levy, EM | 1 |
| Black, PH | 1 |
| Kreiner, PW | 1 |
| Gold, CJ | 1 |
| Keirns, JJ | 1 |
| Brock, WA | 1 |
| Bitensky, MW | 1 |
1 review available for indomethacin and Malignant Melanoma
| Article | Year |
|---|---|
Prostaglandins and metastasis.
Topics: Animals; Cell Line; Cytotoxicity, Immunologic; Immunity, Innate; Indomethacin; Interferons; Killer C | 1983 |
8 trials available for indomethacin and Malignant Melanoma
| Article | Year |
|---|---|
Sustained indomethacin and ranitidine with intermittent continuous infusion interleukin-2 in advanced malignant melanoma: a phase II study.
Topics: Adult; Aged; Female; Humans; Indomethacin; Infusions, Intravenous; Interleukin-2; Lymphocyte Subsets | 1993 |
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Female; HLA-B | 1996 |
Oral indomethacin and ranitidine in advanced melanoma: a phase II study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antin | 1996 |
Effect of T-activin therapy on indomethacin modulation of lymphoproliferative response in vitro of melanoma patients.
Topics: Adjuvants, Immunologic; Adult; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; D | 1998 |
Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Indomethacin; Inter | 1992 |
Indomethacin, ranitidine, and interleukin-2 in melanoma.
Topics: Colorectal Neoplasms; Drug Therapy, Combination; Humans; Indomethacin; Interleukin-2; Kidney Neoplas | 1992 |
Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Indomethacin; Interferon Type I; Kil | 1989 |
Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin.
Topics: Adult; Aged; Cytotoxicity, Immunologic; Drug Administration Schedule; Female; Fever; Humans; Hypoten | 1988 |
36 other studies available for indomethacin and Malignant Melanoma
| Article | Year |
|---|---|
Anti-Melanoma Activity of Indomethacin Incorporated into Mesoporous Silica Nanoparticles.
Topics: Animals; Antineoplastic Agents; Caspase 3; Cell Line, Tumor; Cyclooxygenase 2; Drug Carriers; Drug D | 2020 |
Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Line, Tumor; Down-Regulation; Drug Resistan | 2014 |
Indomethacin to the rescue of TRAIL-resistant melanomas.
Topics: Humans; Indomethacin; Inhibitor of Apoptosis Proteins; Melanoma; Receptors, TNF-Related Apoptosis-In | 2014 |
JID VisualDx quiz: May 2014.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Indomethacin; Melanoma; Skin Neoplasms | 2014 |
Leukotriene B4 creates a favorable microenvironment for murine melanoma growth.
Topics: Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Carrageenan; Cell Growth Processes; Cell Line, Tumo | 2009 |
Suppression of accelerated tumor growth in surgical wounds by celecoxib and indomethacin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma; Carcinoma, Squamous Cell; Celecoxib; Ce | 2005 |
Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice.
Topics: Animals; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Indomethac | 2005 |
Suppressor cells in melanoma and lung cancer: correlation with the clinical stage.
Topics: Adult; Aged; Humans; Indomethacin; Lung Neoplasms; Melanoma; Middle Aged; Neoplasm Staging; Phytohem | 1983 |
Inhibition of lymphocyte response by prostaglandin-producing suppressor cells in patients with melanoma.
Topics: Dinoprostone; Humans; Indomethacin; Lymphocyte Activation; Melanoma; Prostaglandins E; T-Lymphocytes | 1983 |
Immune modulatory effects of indomethacin in melanoma patients are not related to prostaglandin E2-mediated suppression.
Topics: Adult; Aged; Carbazoles; Concanavalin A; Cyclic AMP; Humans; Immunity; Immunosuppression Therapy; In | 1982 |
[Control of multiple skin and lung metastasis of malignant melanoma by combined DAV and OK-432 chemoimmunotherapy in association with large-scale administration of indomethacin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Humans; Indomethacin; Lung Neopla | 1984 |
Natural thermal resistance of human tumor cells and the role of prostaglandin.
Topics: Cell Line; Cell Membrane; Dinoprostone; Drug Evaluation; Hot Temperature; Humans; Indomethacin; Mela | 1983 |
Amplification by macrophages of prostaglandin-mediated immunosuppression in mice bearing syngeneic tumors.
Topics: Animals; Antibody Formation; Cell Line; Culture Media; Fibrosarcoma; Immune Tolerance; Indomethacin; | 1984 |
Increased sensitivity to indomethacin of mice bearing the BCL1-leukemia.
Topics: Animals; Blood Cell Count; Cell Line; Dose-Response Relationship, Drug; Female; Indomethacin; Leukem | 1984 |
The interactions between indomethacin and cytotoxic drugs in mice bearing B-16 melanomas.
Topics: 16,16-Dimethylprostaglandin E2; Animals; Cell Count; Cell Division; Doxorubicin; Female; Fluorouraci | 1980 |
Indomethacin enhancement of immunocompetence in melanoma patients.
Topics: Adult; Age Factors; Aged; Concanavalin A; Humans; Immunocompetence; Indomethacin; Lymphocyte Activat | 1981 |
Prostaglandin E2 modulation of human monocyte antibody-dependent cell-mediated cytotoxicity against human red blood cells.
Topics: Antibody-Dependent Cell Cytotoxicity; Dose-Response Relationship, Drug; Erythrocytes; Humans; Indome | 1982 |
Influence of PGE on the immune response in melanoma-bearing mice.
Topics: Agglutinins; Animals; Antibody-Producing Cells; Cell Transformation, Neoplastic; Female; Hypersensit | 1980 |
Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Carcinoma, Squamou | 1995 |
Human pulmonary macrophages utilize prostaglandins and transforming growth factor beta 1 to suppress lymphocyte activation.
Topics: Adult; Antibodies; Bronchoalveolar Lavage Fluid; Cell Communication; Cells, Cultured; Cytotoxicity, | 1993 |
Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells.
Topics: Animals; Arachidonic Acid; Caffeine; Collagen; Cyclooxygenase Inhibitors; Dinoprost; Drug Combinatio | 1996 |
Effect of vitamin E and indomethacin treatment on adenylate cyclase activity, PGE2 and cAMP levels in murine melanoma cells.
Topics: Adenylyl Cyclases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Cyclic AMP; Dino | 1997 |
Release of active tissue factor by human arterial smooth muscle cells.
Topics: Aorta; Cells, Cultured; Coronary Vessels; Humans; Indomethacin; Interleukin-1; Kinetics; Melanoma; M | 2000 |
Prostaglandin D2 controls pulmonary metastasis of malignant melanoma cells.
Topics: Animals; Cyclooxygenase Inhibitors; Indomethacin; Lung Neoplasms; Melanoma; Mice; Neoplasm Metastasi | 1979 |
Effect of indomethacin on blastogenesis of lymphocytes from cancer patients: differentiation of patient types.
Topics: Humans; Immunity, Cellular; Indomethacin; Leiomyosarcoma; Lung Neoplasms; Lymphocyte Activation; Lym | 1979 |
Inhibition of tumour growth in vivo and in vitro by prostaglandin E.
Topics: Animals; Cell Division; Female; Hydrocortisone; Indomethacin; Melanoma; Mice; Mice, Inbred C57BL; Ne | 1976 |
[Therapeutic response of interferon-beta in malignant melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; | 1986 |
Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relatio | 1989 |
Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.
Topics: Cytotoxicity, Immunologic; Glycoproteins; Humans; Indomethacin; Interleukin-2; Killer Cells, Natural | 1989 |
Toxicity of tumor necrosis factor is synergistic with gamma-interferon and can be reduced with cyclooxygenase inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bone Marrow; Cyclooxygenase Inhibi | 1987 |
Differential distribution of B16F10 melanoma cells in the liver lobule.
Topics: Animals; Cell Line; Female; Indomethacin; Liver Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strain | 1988 |
In vitro inhibition of interleukin-2 production by peripheral blood lymphocytes from stage III melanoma patients by prostaglandin E2: enhancement of lymphocyte proliferation by exogenous interleukin-2 plus indomethacin.
Topics: Concanavalin A; Dinoprostone; Female; Humans; In Vitro Techniques; Indomethacin; Interleukin-2; Lymp | 1986 |
Influence in vitro on NK and K cell activities by cimetidine and indomethacin with and without simultaneous exposure to interferon.
Topics: Antibody-Dependent Cell Cytotoxicity; Carcinoma; Cimetidine; Colonic Neoplasms; Cytotoxicity, Immuno | 1985 |
Role of interleukin 1 in promoting human monocyte-mediated tumor cytotoxicity.
Topics: Cell Adhesion; Cell Line; Cell Separation; Cytotoxicity, Immunologic; Endotoxins; Humans; Indomethac | 1985 |
Inhibition of recombinant interferon-gamma-induced Ia antigen expression by shed B16 F10 melanoma cell membrane vesicles.
Topics: Animals; Cell Adhesion; Cell Membrane; Cells, Cultured; Genes, MHC Class II; Histocompatibility Anti | 1985 |
Hormonal control of melanocytes: MSH-sensitive adenyl cyclase in the Cloudman melanoma.
Topics: Acetates; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Calcium; Chelating Agents; Enzyme | 1973 |